Dalstep Tablet ER (Dalfampridine) | Used for Multiple Sclerosis Walking Difficulty
Dalstep Tablet ER contains Dalfampridine, a potassium channel blocker used to improve walking ability in patients with multiple sclerosis (MS). It works by enhancing nerve signal transmission, helping MS patients gain better mobility and muscle function.
Product Overview
Dalstep Tablet ER is a specialized prescription medication engineered to improve walking ability and lower limb mobility in adult patients diagnosed with multiple sclerosis. This advanced extended release oral medication acts directly on the central nervous system to address severe walking difficulty and leg muscle weakness. By offering a steady therapeutic effect, this formulation helps individuals maintain a more consistent walking speed, enhances daily physical endurance, and supports long-term independence for patients managing progressive multiple sclerosis symptoms.
Product Composition
Primary Active Ingredient: Each individual tablet delivers Dalfampridine 10mg directly to the systemic circulation.
Drug Delivery System: Utilizes a specialized matrix designed for controlled release, ensuring a steady plasma concentration over a twelve-hour period.
Core Excipients: Manufactured using high-quality pharmaceutical polymers, microcrystalline cellulose, magnesium stearate, and an optimized film coating.
Product Specification
| Attribute | Standard Compliance |
| Product Identifier | Dalstep Tablet ER |
| Active Formula | Dalfampridine |
| Strength | 10mg |
| Delivery Category | Oral Extended Release |
| Target Condition | Neurological walking impairment |
| Routine Schedule | One tablet every twelve hours |
Mechanism of Action
- Selective Channel Targeting: Functions as a potent potassium channel blocker within the central nervous system pathways.
- Action Potential Stabilization: Blocks leaking potassium currents in demyelinated axons, which restores the strength of electrical impulses.
- Neurotransmitter Conduction Enhancement: Boosts neurotransmitter conduction across damaged nerve fibers to improve signals traveling to skeletal muscles.
- Neuromuscular Efficiency: Optimizes the communication bridge between the brain and the legs, allowing more fluid and reliable physical movement.
Key Benefits
- Measurable Walking Velocity: Clinically optimized to increase walking velocity and performance during daily activities.
- Optimized Gait Balance: Reduces stumbling and lower-limb dragging by improving overall muscle coordination and joint stability.
- Continuous Twelve Hour Relief: The specialized extended release formulation prevents sudden drops in drug effectiveness, ensuring steady, all-day mobility.
- Daily Functional Independence: Empowers patients to complete routine tasks, run errands, and move around with noticeably less physical fatigue.
Usage
Proper administration of this extended release oral medication is absolutely critical to guarantee patient safety and achieve the best therapeutic outcomes. The outlined guidelines must be strictly followed to prevent accidental drug toxicity.
Standard Therapeutic Dosage: The standard prescribed dose for adult patients is one Dalfampridine 10mg tablet taken twice every single day.
Strict Interval Timing: Doses must be spaced precisely twelve hours apart to maintain a safe, continuous, and steady concentration of the drug in the bloodstream.
Whole Tablet Administration: Every tablet must be swallowed completely whole with a full glass of water. It can be taken either with or without food.
Missed Dose Protocol: If a dose is missed by a few hours, skip it completely and wait until the next regularly scheduled interval.
Administration Schedules
| Administrative Parameter | Required Protocol | Safety Justification |
| Max Daily Limit | Exactly two tablets per twenty four hours | Exceeding this limit substantially raises the risk of severe seizures |
| Tablet Integrity | Do not crush, chew, split, or dissolve | Breaking the protective shell destroys the extended release formulation |
| Schedule Adjustments | No double dosing allowed under any circumstances | Rapid absorption of the active compound triggers acute central nervous system toxicity |
| Renal Tracking | Prior kidney function screening is mandatory | Compromised kidneys cannot clear the medicine effectively from the body |
Uses
Dalstep Tablet ER is an advanced prescription treatment specifically targeted to address neurological walking deficits in individuals navigating chronic nerve disorders. The primary Dalfampridine uses focus on restoring motor communication within the body.
Improvement of Walking Ability: Primarily indicated to help adults diagnosed with multiple sclerosis maximize their overall walking performance and baseline gait stability.
Enhancement of Walking Velocity: Works directly on compromised pathways within the central nervous system to visibly accelerate walking speed and coordination during daily physical routines.
Management of Mobility Challenges: Aids in minimizing severe walking difficulty caused by ongoing myelin sheath degradation across all major sub-types of the condition.
Lower Limb Strength Support: Indirectly helps patients stabilize their physical balance and reduce leg muscle weakness by facilitating steady nerve signal conduction to the lower extremities.
FAQs
Q: What is the product used for?
A: Dalstep Tablet ER is a specialized prescription formula clinically indicated to help improve walking ability and increase walking speed in adult patients living with multiple sclerosis. It is designed to minimize walking difficulty by optimizing nerve transmissions affected by the condition.
Q: What is the primary active component in this medication?
A: Every single tablet contains Dalfampridine 10mg as the core therapeutic agent, carefully balanced inside an advanced oral matrix.
Q: How long does it take to see a noticeable improvement in walking speed?
A: Most patients begin to notice a positive change in their walking velocity and performance within two to four weeks of starting continuous treatment, though full benefits can sometimes take up to six weeks to develop.
Q: What is the recommended daily dosage schedule?
A: The standard therapeutic schedule is one tablet taken orally twice daily. It is critical to space the doses exactly twelve hours apart to maintain a steady plasma concentration of the extended release oral medication.
Q: Can the tablet be split or crushed for easier swallowing?
A: No, you must swallow the tablet entirely whole. Breaking, crushing, chewing, or dissolving the tablet disrupts the specialized extended release formulation, which causes the active drug to enter the body too fast and significantly elevates the risk of severe side effects.
Q: Who should avoid taking this drug?
A: This medication is strictly contraindicated for anyone with a known history of seizures or epilepsy. It should also be avoided by individuals diagnosed with moderate to severe kidney impairment, as compromised renal function slows drug clearance and increases toxicity risks.
Q: What are the most common side effects reported during treatment?
A: The most frequently documented mild reactions include dizziness, insomnia or trouble sleeping, nausea, headaches, minor balance issues, and a higher vulnerability to developing a urinary tract infection.
Q: What should be done if a scheduled dose is missed?
A: If a dose is missed, skip that dose entirely and take the next scheduled tablet at your regular time. Never double the dose to make up for a missed one, as exceeding the specified amount increases the danger of experiencing seizures.
Interactions
Dalstep Tablet ER (Dalfampridine) may interact with certain medicines and health conditions. These interactions can affect how the medicine works or increase the risk of side effects.
| Interaction Type | Details |
|---|---|
| Kidney Medicines | May increase medicine levels in the body. |
| Seizure Medicines | May affect seizure risk. |
| Other Dalfampridine Products | Avoid taking together. |
| OTC Medicines | Some may affect treatment response. |
| Herbal Supplements | Tell about herbs or supplements used. |
| Alcohol | May worsen dizziness in some people. |
| Medical Conditions | Kidney disease may increase side effects. |
Medicines That May Interact
- Medicines used for kidney-related conditions
- Drugs that lower seizure threshold
- Other medicines containing Dalfampridine
- Certain vitamins, supplements, or herbal products
Things to Keep in Mind
- Share a list of all medicines you use
- Avoid starting new medicines without advice
- Inform about existing medical conditions
- Report unusual symptoms after combining medicines
| Manufacturer | : | Sun Pharma, India |
| Trade Name | : | Ampyra |
| Generic Search | : | Dalfampridine |
| Strength | : | 10mg |
Latest Products
